Compare MPLX LP (MPLX) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? MPLX LP trades at $57.5 (market cap $57.70B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: MPLX LP is far larger — about 59× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and MPLX LP pays a 7.57% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| MPLX | MRVI | |
|---|---|---|
Market Cap | $57.70B | $977.37M |
Volume | 561,167 | 2,742,564 |
Sector | Energy | Health |
52-Week High | $60.51 | $9.00 |
52-Week Low | $48.53 | $2.83 |
Enterprise Value | $82.80B | $1.08B |
Dividend Yield | 7.57% | — |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $56.91, up 0.14% with a bearish technical signal despite strong fundamentals. The company reported $11.47B revenue and $4.91B net income for 2025, with robust profitability margins (40.45% net margin, 33.95% ROE). Recent earnings show mixed results with Q4 2025 beat but Q1 and Q2 2026 misses. Analyst consensus remains strongly bullish with 19 buy ratings and a $63.80 price target, representing 12% upside potential.
The investment case balances strong cash flow generation and dividend yield against energy market volatility risks. MPLX's fee-based midstream model provides revenue stability, but recent technical weakness and earnings misses warrant caution. The stock offers value with a 12.24 P/E ratio and dividend income potential, though investors should monitor Q3 2026 earnings due November 3rd for confirmation of business momentum.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
